Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Lymphoma
7m 1s
EHA 2022 Updates : Lymphoma
Published 11 Jul 2022
EHA 2022 saw exciting progress particularly from the perspective of Bispecific Antibodies and CAR -T cell therapy & utility of new treatments in elderly patients. A phase 2 clinical trial of Epcoritamab in DLBCL patients who have received a median of three prior lines of treatments showed a complete response (CR) rate of 39 percent. ZUMA-7 study subgroup analysis showed significant EFS & quality of life benefit for axicabtagene ciloleucel in elderly large B cell lymphoma patients >65 years of age. SHINE study combining ibrutinib with bendamustine-rituximab and rituximab maintenance in older patients with untreated mantle cell lymphoma showed meaningful improvement in the PFS.
